RT Journal Article SR Electronic T1 Bicentric evaluation of stabilizing sampling tubes for assessment of monocyte HLA-DR expression in clinical samples JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2021.05.12.21256300 DO 10.1101/2021.05.12.21256300 A1 Sarah Hamada A1 Robin Jeannet A1 Morgane Gossez A1 Martin Cour A1 Laurent Argaud A1 Bruno Francois A1 Thomas Daix A1 Fabienne Venet A1 Guillaume Monneret YR 2021 UL http://medrxiv.org/content/early/2021/05/17/2021.05.12.21256300.abstract AB Background Diminished expression of human leukocyte antigen DR on circulating monocytes (mHLA-DR), measured by standardized flow cytometry procedure, is a reliable indicator of immunosuppression in severely injured intensive care unit patients. As such, it is used as stratification criteria in clinical trials evaluating novel immunostimulating therapies. Pre-analytical constraints relative to the short delay between blood sampling and flow cytometry staining have nevertheless limited its use in multicentric studies. The objective of the present work was to compare mHLA-DR expression between whole blood samples simultaneously drawn in EDTA or Cyto-Chex® BCT tubes.Methods In 2 university hospitals, mHLA-DR was assessed in fresh whole blood from septic patients (n = 12) and healthy donors (n = 6) simultaneously sampled on EDTA and Cyto-Chex® BCT tubes. Staining was performed immediately after sampling and after blood storage at room temperature.Results We observed the remarkable stability of mHLA-DR results when blood was collected in Cyto-Chex® BCT tubes (until 48-72 h). On baseline values, despite good correlation between tubes (r = 0.98, p< 0.001), mHLA-DR expression was systematically lower with Cyto-Chex® BCT.Conclusion The present reports confirms the great potential of Cyto-Chex® BCT tubes to delay mHLA-DR staining in centers without rapid access to flow cytometry facilities. However, a 30 % gap exists between results obtained with EDTA and Cyto-Chex® BCT tubes. As current thresholds for clinical decisions were obtained with EDTA samples, further studies are needed to confirm clinical thresholds with Cyto-Chex® BCT tubes.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT04392401Funding StatementNoneAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This project was part of an ongoing prospective observational clinical study (RICO, REA-IMMUNO-COVID). It was approved by ethics committee (Comite de Protection des Personnes Ile de France 1 - IRB/IORG #: IORG0009918) under agreement number 2020-A01079-30. This clinical study was registered at ClinicalTrials.gov (NCT04392401). The committee waived the need for written informed consent because the study was observational, with a low risk to patients, and no specific procedure, other than routine blood sampling, was required. Oral information and nonopposition to inclusion in the study were mandatory and were systematically obtained before any blood sample was drawn. All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData available upon request